Insider Transactions in Q1 2024 at Neurocrine Biosciences Inc (NBIX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 06
2024
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,121
-4.88%
|
$159,182
$142.24 P/Share
|
|
Feb 06
2024
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
3,040
-0.6%
|
$431,680
$142.18 P/Share
|
|
Feb 06
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,280
-3.2%
|
$181,760
$142.12 P/Share
|
|
Feb 06
2024
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,600
-1.19%
|
$227,200
$142.2 P/Share
|
|
Feb 06
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,280
-4.17%
|
$181,760
$142.19 P/Share
|
|
Feb 01
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
623
-8.32%
|
$86,597
$139.77 P/Share
|
|
Jan 31
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,250
-3.27%
|
$175,000
$140.65 P/Share
|
|
Jan 31
2024
|
Jude Onyia Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
126
-1.05%
|
$17,766
$141.94 P/Share
|
|
Jan 31
2024
|
Eiry Roberts Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,457
-6.54%
|
$203,980
$140.79 P/Share
|
|
Jan 31
2024
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
2,707
-0.54%
|
$378,980
$140.69 P/Share
|
|
Jan 31
2024
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,541
-1.16%
|
$215,740
$140.7 P/Share
|
|
Jan 31
2024
|
Julie Cooke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,740
-4.69%
|
$245,340
$141.32 P/Share
|
|
Jan 31
2024
|
Ingrid Delaet Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
422
-6.27%
|
$59,502
$141.94 P/Share
|
|
Jan 31
2024
|
Eric Benevich Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,207
-3.11%
|
$168,980
$140.78 P/Share
|
|
Jan 31
2024
|
David W. Boyer Chief Corp. Affairs Officer |
SELL
Open market or private sale
|
Direct |
2,096
-16.32%
|
$293,440
$140.79 P/Share
|
|
Jan 31
2024
|
Matt Abernethy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,283
-4.34%
|
$179,620
$140.72 P/Share
|
|
Jan 22
2024
|
Darin Lippoldt Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-21.8%
|
$1,390,000
$139.86 P/Share
|
|
Jan 22
2024
|
Darin Lippoldt Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+17.89%
|
$790,000
$79.02 P/Share
|
|
Jan 09
2024
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
62,023
-11.04%
|
$8,311,082
$134.01 P/Share
|
|
Jan 09
2024
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
62,023
+9.94%
|
$1,178,437
$19.59 P/Share
|
|
Jan 08
2024
|
Kevin Charles Gorman Director |
SELL
Open market or private sale
|
Direct |
105,835
-17.48%
|
$13,970,220
$132.44 P/Share
|
|
Jan 08
2024
|
Kevin Charles Gorman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,835
+14.88%
|
$2,010,865
$19.59 P/Share
|
|
Jan 02
2024
|
Kyle Gano Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
75,000
-19.54%
|
$9,825,000
$131.46 P/Share
|
|
Jan 02
2024
|
Kyle Gano Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+15.0%
|
$1,425,000
$19.59 P/Share
|
|
Jan 02
2024
|
William H Rastetter Director |
SELL
Open market or private sale
|
Direct |
11,044
-17.59%
|
$1,446,764
$131.47 P/Share
|
|
Jan 02
2024
|
William H Rastetter Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+24.16%
|
$240,000
$12.98 P/Share
|